Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART
The integrase strand transfer inhibitor, dolutegravir (DTG), is widely used in first- and second-line antiretroviral therapy (ART) regimens in South Africa. We describe an adult with virological failure on second-line tenofovir/lamivudine/dolutegravir (TLD2) and rapid emergence of DTG resistance wit...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2025-04-01
|
| Series: | Southern African Journal of HIV Medicine |
| Subjects: | |
| Online Access: | https://sajhivmed.org.za/index.php/hivmed/article/view/1701 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850144362125590528 |
|---|---|
| author | Kirusha Naidoo Richard J. Lessells Jienchi Dorward Mahomed Y.S. Moosa Yukteshwar Sookrajh Pravi Moodley Paul K. Drain Nigel Garrett |
| author_facet | Kirusha Naidoo Richard J. Lessells Jienchi Dorward Mahomed Y.S. Moosa Yukteshwar Sookrajh Pravi Moodley Paul K. Drain Nigel Garrett |
| author_sort | Kirusha Naidoo |
| collection | DOAJ |
| description | The integrase strand transfer inhibitor, dolutegravir (DTG), is widely used in first- and second-line antiretroviral therapy (ART) regimens in South Africa. We describe an adult with virological failure on second-line tenofovir/lamivudine/dolutegravir (TLD2) and rapid emergence of DTG resistance within 3 months, while receiving rifapentine-based tuberculosis preventive therapy. |
| format | Article |
| id | doaj-art-539a39d4a74946d2a49f9c7236ddaf72 |
| institution | OA Journals |
| issn | 1608-9693 2078-6751 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | AOSIS |
| record_format | Article |
| series | Southern African Journal of HIV Medicine |
| spelling | doaj-art-539a39d4a74946d2a49f9c7236ddaf722025-08-20T02:28:24ZengAOSISSouthern African Journal of HIV Medicine1608-96932078-67512025-04-01261e1e310.4102/sajhivmed.v26i1.1701901Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ARTKirusha Naidoo0Richard J. Lessells1Jienchi Dorward2Mahomed Y.S. Moosa3Yukteshwar Sookrajh4Pravi Moodley5Paul K. Drain6Nigel Garrett7Department of HIV Vaccines and Pathogenesis, Centre for the AIDS Programme of Research in South Africa (CAPRISA), DurbanDepartment of HIV Vaccines and Pathogenesis, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa; and, KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), College of Health Sciences, University of KwaZulu-Natal, DurbanDepartment of HIV Vaccines and Pathogenesis, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa; and, Nuffield Department of Primary Care Health Sciences, University of Oxford, OxfordDepartment of Infectious Diseases, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, DurbaneThekwini Municipality Health Unit, DurbanDepartment of Virology, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa; and, Department of Virology, National Health Laboratory Service, Inkosi Albert Luthuli Central Hospital, DurbanDepartment of Epidemiology, University of Washington, Seattle, Washington, United States of America; and, Department of Global Health, University of Washington, Seattle, Washington, United States of America; and, Department of Medicine, University of Washington, Seattle, WashingtonDepartment of HIV Vaccines and Pathogenesis, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa; and, Department of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, DurbanThe integrase strand transfer inhibitor, dolutegravir (DTG), is widely used in first- and second-line antiretroviral therapy (ART) regimens in South Africa. We describe an adult with virological failure on second-line tenofovir/lamivudine/dolutegravir (TLD2) and rapid emergence of DTG resistance within 3 months, while receiving rifapentine-based tuberculosis preventive therapy.https://sajhivmed.org.za/index.php/hivmed/article/view/1701drug resistancedolutegravir resistancedrug-drug interactiondolutegravirrifapentine. |
| spellingShingle | Kirusha Naidoo Richard J. Lessells Jienchi Dorward Mahomed Y.S. Moosa Yukteshwar Sookrajh Pravi Moodley Paul K. Drain Nigel Garrett Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART Southern African Journal of HIV Medicine drug resistance dolutegravir resistance drug-drug interaction dolutegravir rifapentine. |
| title | Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART |
| title_full | Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART |
| title_fullStr | Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART |
| title_full_unstemmed | Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART |
| title_short | Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART |
| title_sort | rapid emergence of dolutegravir resistance on second line dolutegravir based art |
| topic | drug resistance dolutegravir resistance drug-drug interaction dolutegravir rifapentine. |
| url | https://sajhivmed.org.za/index.php/hivmed/article/view/1701 |
| work_keys_str_mv | AT kirushanaidoo rapidemergenceofdolutegravirresistanceonsecondlinedolutegravirbasedart AT richardjlessells rapidemergenceofdolutegravirresistanceonsecondlinedolutegravirbasedart AT jienchidorward rapidemergenceofdolutegravirresistanceonsecondlinedolutegravirbasedart AT mahomedysmoosa rapidemergenceofdolutegravirresistanceonsecondlinedolutegravirbasedart AT yukteshwarsookrajh rapidemergenceofdolutegravirresistanceonsecondlinedolutegravirbasedart AT pravimoodley rapidemergenceofdolutegravirresistanceonsecondlinedolutegravirbasedart AT paulkdrain rapidemergenceofdolutegravirresistanceonsecondlinedolutegravirbasedart AT nigelgarrett rapidemergenceofdolutegravirresistanceonsecondlinedolutegravirbasedart |